This review highlights that while half of PPCM patients recover LV function, 10% do not survive, and emphasizes the importance of guideline-directed medical therapy for improved outcomes.
Purpose of review Peripartum cardiomyopathy (PPCM) contributes significantly to maternal morbidity and mortality worldwide. In this review, we describe the present-day epidemiology and current understanding of the pathogenesis of PPCM. We provide an updated approach to diagnosis and management of PPCM, and discuss risk factors and predictors of outcome. Recent findings The highest incidences of PPCM have been reported in African, Asian, and Caribbean populations. Contemporary literature supports a ‘two-hit’ hypothesis, whereby the ‘first hit’ implies a predisposition, and the ‘second hit’ refers to an imbalanced peripartal hormonal milieu that results in cardiomyopathy. Whereas a half of patients will have left ventricular (LV) recovery, a tenth do not survive. Clinical findings and special investigations (ECG, echocardiography, cardiac MRI, biomarkers) can be used for risk stratification. Frequent prescription of guideline-directed medical therapy is associated with improved outcomes. Summary Despite advances in elucidating the pathogenesis of PPCM, it remains unclear why only certain women develop the disease. Moreover, even with better diagnostic work-up and management, it remains unknown why some patients with PPCM have persistent LV dysfunction or die. Future research should be aimed at better understanding of the mechanisms of disease and finding new therapies that could improve survival and LV recovery.
Viljoen et al. (Thu,) studied this question.